Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.

Tsurutani J, Nozawa K, Mukohara T, Taira T, Yoshimura A, Nagai SE, Hashimoto J, Matsuura K, Mizuno T, Shinden Y, Yamamoto M, Takano T, Wakahara M, Terakawa H, Yamanaka T, Kojima Y, Nakayama T, Hirakawa Y, Shiosakai K, Iwata H

Open source

DOI: 10.1016/j.breast.2026.104722
Published: 2026 Apr
Container: Breast (Edinburgh, Scotland)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.breast.2026.104722,
  title = {Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.},
  author = {Tsurutani J and Nozawa K and Mukohara T and Taira T and Yoshimura A and Nagai SE and Hashimoto J and Matsuura K and Mizuno T and Shinden Y and Yamamoto M and Takano T and Wakahara M and Terakawa H and Yamanaka T and Kojima Y and Nakayama T and Hirakawa Y and Shiosakai K and Iwata H},
  year = {2026},
  journal = {Breast (Edinburgh, Scotland)},
  doi = {10.1016/j.breast.2026.104722},
  url = {https://doi.org/10.1016/j.breast.2026.104722}
}

RIS

TY  - JOUR
TI  - Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.
AU  - Tsurutani J
AU  - Nozawa K
AU  - Mukohara T
AU  - Taira T
AU  - Yoshimura A
AU  - Nagai SE
AU  - Hashimoto J
AU  - Matsuura K
AU  - Mizuno T
AU  - Shinden Y
AU  - Yamamoto M
AU  - Takano T
AU  - Wakahara M
AU  - Terakawa H
AU  - Yamanaka T
AU  - Kojima Y
AU  - Nakayama T
AU  - Hirakawa Y
AU  - Shiosakai K
AU  - Iwata H
PY  - 2026
JO  - Breast (Edinburgh, Scotland)
DO  - 10.1016/j.breast.2026.104722
UR  - https://doi.org/10.1016/j.breast.2026.104722
ER  -

APA

J, T., K, N., T, M., T, T., A, Y., SE, N., J, H., K, M., T, M., Y, S., M, Y., T, T., M, W., H, T., T, Y., Y, K., T, N., Y, H., K, S., & H, I. (2026). Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease.. Breast (Edinburgh, Scotland). https://doi.org/10.1016/j.breast.2026.104722

Source records

pubmed · retrieved 2026-09-26T02:25:04.106Z